Efficacy of oralTranexamicAcid in melasma
Phase 3
Recruiting
- Conditions
- Melasema.Chloasma
- Registration Number
- IRCT20180111038311N1
- Lead Sponsor
- Ahvaz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 62
Inclusion Criteria
Patients with melasma with 18- 60 years old rang.
Exclusion Criteria
Patients with coagulopathy
Patients with thrombotic complications
Any of thrombotic events
Use of anticoagulant drugs or anti-platelet such as aspirin or Clopidogrel
Pregnancy, lactation, concomitant use of contraceptives,
The history of vitiligo or other pigmentation disorders,
Trancexamic Acid Sensitivity History
renal failure
History of treatment for melasma with clarifying drugs in 3 months before the start of the study.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Pigmentation. Timepoint: MASIS record before intervention - one month and three months after intervention. Method of measurement: MASI Score.
- Secondary Outcome Measures
Name Time Method Gastrointestinal complications. Timepoint: before intervention - one month and three months after intervention. Method of measurement: Ask the patients.;Hypomenorea. Timepoint: before intervention - one month and three months after intervention. Method of measurement: ASk the patients.